Kronos Bio, Inc. (—): restructuring charge disclosed in 8-K

Kronos Bio, Inc.: restructuring charge — Kronos Bio cuts workforce by 21%, extends cash runway into H2 2026

Kronos Bio, Inc.

Board approved ~21% workforce reduction; completion expected March 7, 2024.

Expects ~$0.5M in cash severance charges in Q1 2024, and up to ~$0.1M for COBRA.

Existing cash resources expected to support operations into second half of 2026.

Key facts

Extracted from this filing and checked against the source text.

Restructurings & Charges SEC 8-K Item 2.05/2.06 confidence 0.9

Kronos Bio, Inc. announced a restructuring with charges of approximately $0.5 million associated with cash severance payments primarily in the first quarter of 2024, and up to approximately $0.1 million in charges assoc (approximately 21% reduction in its workforce).

Type: restructuring
Charge: approximately $0.5 million associated with cash severance payments primarily in the first quarter of 2024, and up to approximately $0.1 million in charges assoc
Headcount: approximately 21% reduction in its workforce

Exact text from the filing

On March 5, 2024, the Board of Directors of Kronos Bio, Inc. (the “Company”) approved an approximately 21% reduction in its workforce as part of a strategic resource allocation and cost containment plan. The workforce reduction is expected to be completed on March 7, 2024. In connection with the reduction in workforce, the Company expects to incur charges of approximately $0.5 million associated with cash severance payments primarily in the first quarter of 2024, and up to approximately $0.1 million in charges associated with cash payments for COBRA reimbursement over up to the next six months.

View on SEC.gov